- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Contract research organizations aren't without risks of course, but they do offer some protection against the vagaries of the industry.
Shares rise 5.4% on the news.
Despite the Vytorin setback, the focus here should be on drugs in development, not products in the market.
Merck, Pfizer and others are getting used to a new world that requires cost discipline.
If a recession can be avoided, 2008, like last year, could be active for initial issues.
Several firms are debating whether to bulk up or shed lower-margin units.
Here's what you need to know about buying these rare, tradition-rich pieces from the Canadian islands.
It can be done, but it will probably require some tough choices.
Shares have dropped more than 30% since May, but questions remain about its model.
Will that change when earnings arrive Thursday?